Base de dados : MEDLINE
Pesquisa : C23.550.081 [Categoria DeCS]
Referências encontradas : 12435 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1244 ir para página                         

  1 / 12435 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465591
[Au] Autor:Wang H; Lu SC; He L; Dong JH
[Ad] Endereço:Department of Hepatobiliary Surgery, The General Hospital of the People's Liberation army.
[Ti] Título:A study on risk factors and diagnostic efficiency of posthepatectomy liver failure in the nonobstructive jaundice.
[So] Source:Medicine (Baltimore);97(8):e9963, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Liver failure remains as the most common complication and cause of death after hepatectomy, and continues to be a challenge for doctors.t test and χ test were used for single factor analysis of data-related variables, then results were introduced into the model to undergo the multiple factors logistic regression analysis. Pearson correlation analysis was performed for related postoperative indexes, and a diagnostic evaluation was performed using the receiver operating characteristic (ROC) of postoperative indexes.Differences in age, body mass index (BMI), portal vein hypertension, bile duct cancer, total bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), operation time, cumulative portal vein occlusion time, intraoperative blood volume, residual liver volume (RLV)/entire live rvolume, ascites volume at postoperative day (POD)3, supplemental albumin amount at POD3, hospitalization time after operation, and the prothrombin activity (PTA) were statistically significant. Furthermore, there were significant differences in total bilirubin and the supplemental albumin amount at POD3. ROC analysis of the average PTA, albumin amounts, ascites volume at POD3, and their combined diagnosis were performed, which had diagnostic value for postoperative liver failure (area under the curve (AUC): 0.895, AUC: 0.798, AUC: 0.775, and AUC: 0.903).Preoperative total bilirubin level and the supplemental albumin amount at POD3 were independent risk factors. PTA can be used as the index of postoperative liver failure, and the combined diagnosis of the indexes can improve the early prediction of postoperative liver failure.
[Mh] Termos MeSH primário: Hepatectomia/efeitos adversos
Icterícia/sangue
Falência Hepática/etiologia
Complicações Pós-Operatórias
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Área Sob a Curva
Ascite/etiologia
Bilirrubina/sangue
Índice de Massa Corporal
Distribuição de Qui-Quadrado
Criança
Pré-Escolar
Feminino
Seres Humanos
Hipertensão Portal/complicações
Hipertensão Portal/cirurgia
Lactente
Icterícia/cirurgia
Testes de Função Hepática
Neoplasias Hepáticas/complicações
Neoplasias Hepáticas/cirurgia
Modelos Logísticos
Masculino
Meia-Idade
Duração da Cirurgia
Período Pós-Operatório
Valor Preditivo dos Testes
Período Pré-Operatório
Tempo de Protrombina
Curva ROC
Estudos Retrospectivos
Fatores de Risco
Albumina Sérica/análise
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Serum Albumin); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009963


  2 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465550
[Au] Autor:Kim SH; Choi YH; Kim JW; Oh S; Lee S; Kim BG; Lee KL
[Ad] Endereço:Department of Internal Medicine.
[Ti] Título:Clinical significance of computed tomography-detected ascites in gastric cancer patients with peritoneal metastases.
[So] Source:Medicine (Baltimore);97(8):e9343, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients with peritoneal metastases (PM) are generally considered incurable; therefore, the presence of PM is a critical factor in deciding between palliative surgery and curative resection as a therapeutic strategy. Previous studies have not determined the predictive value of ascites detected on computed tomography (CT) for the presence of PM. We aimed to analyze the factors that are associated with PM in patients with CT-detected ascites.A total of 2207 consecutive patients who were diagnosed with gastric cancer between 2004 and 2013 were identified. Eleven patients with liver cirrhosis or chronic renal insufficiency with ascites and 57 patients who received previous treatment were excluded. Ninety-eight patients who had definite evidence of distant metastasis or PM on CT and 64 patients who did not undergo surgery were excluded. A total of 91 patients were enrolled in the study to analyze the association between CT-detected ascites and surgically confirmed PM.Seventy-six patients underwent curative resection and 15 patients underwent palliative surgery. Twelve patients exhibited peritoneal seeding and 37 patients showed regional lymph node metastasis. Regional lymph node metastasis, advanced gastric cancer, undifferentiated pathology, and the amount of ascites were significantly associated with PM. Multivariable logistic regression analysis identified the amount of ascites to be an independent risk factor for the presence of PM.Regional lymph node metastasis, advanced gastric cancer, undifferentiated pathology, and the amount of ascites were associated with PM. The amount of ascites was found to be an independent risk factor for PM.
[Mh] Termos MeSH primário: Ascite/diagnóstico por imagem
Neoplasias Peritoneais/diagnóstico por imagem
Neoplasias Gástricas/diagnóstico por imagem
Estômago/diagnóstico por imagem
Tomografia Computadorizada por Raios X/métodos
[Mh] Termos MeSH secundário: Ascite/etiologia
Feminino
Seres Humanos
Linfonodos/diagnóstico por imagem
Linfonodos/patologia
Metástase Linfática
Masculino
Meia-Idade
Neoplasias Peritoneais/secundário
Peritônio/diagnóstico por imagem
Peritônio/patologia
Estudos Retrospectivos
Estômago/patologia
Neoplasias Gástricas/complicações
Neoplasias Gástricas/patologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009343


  3 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468865
[Au] Autor:Husain H; Nykin D; Bui N; Quan D; Gomez G; Woodward B; Venkatapathy S; Duttagupta R; Fung E; Lippman SM; Kurzrock R
[Ad] Endereço:Division of Hematology and Oncology, University of California San Diego, San Diego, California. hhusain@ucsd.edu.
[Ti] Título:Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.
[So] Source:Mol Cancer Ther;16(5):948-955, 2017 May.
[Is] ISSN:1538-8514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Collection of cell-free DNA (cfDNA) from the blood of individuals with cancer has permitted noninvasive tumor genome analysis. Detection and characterization of cfDNA in ascites and pleural effusions have not yet been reported. Herein, we analyzed cfDNA in the ascites and pleural effusions from six individuals with metastatic cancer. In all cases, cfDNA copy number variations (CNV) were discovered within the effusate. One individual had a relevant alteration with a high copy amplification in in a never smoker with lung cancer, who showed only and amplification in a prior tissue biopsy. Another subject with metastatic breast cancer had cytology-positive ascites and an activating mutation identified in the tissue, blood, and ascites collectively. This individual had tumor regression after the administration of the mTOR inhibitor everolimus and had evidence of chromotripsis from chromosomal rearrangements noted in the cell-free ascitic fluid. These results indicate that cfDNA from ascites and pleural effusions may provide additional information not detected with tumor and plasma cell-free DNA molecular characterization, and a context for important insights into tumor biology and clonal dynamic change within primary tumor and metastatic deposits. .
[Mh] Termos MeSH primário: Ascite/genética
Ácidos Nucleicos Livres/genética
Genoma Humano/genética
Neoplasias/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Ascite/sangue
Linhagem Celular Tumoral
Ácidos Nucleicos Livres/sangue
Classe I de Fosfatidilinositol 3-Quinases/genética
Quinase 4 Dependente de Ciclina/genética
Variações do Número de Cópias de DNA/genética
Feminino
Seres Humanos
Masculino
Meia-Idade
Mutação
Neoplasias/sangue
Neoplasias/classificação
Neoplasias/patologia
Derrame Pleural/genética
Proteínas Proto-Oncogênicas c-mdm2/genética
Receptor do Fator de Crescimento Epidérmico/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell-Free Nucleic Acids); EC 2.3.2.27 (MDM2 protein, human); EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2); EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases); EC 2.7.1.137 (PIK3CA protein, human); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); EC 2.7.11.22 (CDK4 protein, human); EC 2.7.11.22 (Cyclin-Dependent Kinase 4)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1158/1535-7163.MCT-16-0436


  4 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381963
[Au] Autor:Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Hui K; Hu C; Ren Y; Jiang X
[Ad] Endereço:Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University.
[Ti] Título:Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.
[So] Source:Medicine (Baltimore);96(47):e8725, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib is a novel and highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. There are no reports of concurrent apatinib with gemcitabine in patients with pancreatic cancer-mediated MA. PATIENT CONCERNS: Herein, we presented a 64-year-old man patient who visited hospital due to abdominal pain for 1 month. DIAGNOSES: He was initially diagnosed with pancreatic cancer and his first symptom was MA. INTERVENTIONS: After failing in tube drainage and gemcitabine therapy, the patient received gemcitabine combined apatinib orally and after administrated 1 month, the MA was evaluated as nearly clear response according to the RECIST 1.1 standard, and without further need of paracentesis. The CEA and CA199 reached the lowest level after administrating for 2.5 months during the treatment process. OUTCOMES: 10.5 months following apatinib administration, the patient achieved a progression-free survival for more than 11 months. Hypertension (grade IV), hand-foot syndrome (grade I) and proteinuria (grade II) were observed. LESSONS: It indicated that apatinib concurrent gemcitabine may be a superior choice for pancreatic cancer-mediated MA. Further clinical trials required to confirm its efficacy and safety.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Ascite/tratamento farmacológico
Ascite/etiologia
Desoxicitidina/análogos & derivados
Neoplasias Pancreáticas/complicações
Piridinas/uso terapêutico
[Mh] Termos MeSH secundário: Antineoplásicos/administração & dosagem
Desoxicitidina/administração & dosagem
Desoxicitidina/uso terapêutico
Quimioterapia Combinada
Seres Humanos
Masculino
Meia-Idade
Proteínas Tirosina Quinases/antagonistas & inibidores
Piridinas/administração & dosagem
Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Pyridines); 0W860991D6 (Deoxycytidine); 5S371K6132 (apatinib); B76N6SBZ8R (gemcitabine); EC 2.7.10.1 (Protein-Tyrosine Kinases); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008725


  5 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390520
[Au] Autor:Ye W; Tang Y; Yao C; Shi J; Xu Y; Jiang J
[Ad] Endereço:Department of Tumor Biological Treatment.
[Ti] Título:Advanced gastrointestinal carcinoma with massive ascites and hydrothorax during pregnancy: A case report and review of the literature.
[So] Source:Medicine (Baltimore);96(51):e9354, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Gastrointestinal carcinoma is rare during pregnancy. It is usually diagnosed at an advanced stage because special gastrointestinal symptoms are generally overlooked during pregnancy, and there are many limitations and contraindications for using diagnostic tools during pregnancy. PATIENT CONCERNS: We present a case of a 29-year-old patient with 27 weeks and 5 days of gestation due to massive ascites and hydrothorax. DIAGNOSES: The patient was diagnosed with an advanced gastrointestinal cancer. Pathological report showed poorly differentiated tumor with the signet ring cell component. INTERVENTIONS: Caesarean section was performed. At the same time, an abdominal exploration showed that the omentum was like biscuits . There were extensive and firm intestinal adhesions, and many tumor lesions were found on the surface of greater curvature of stomach, spleen, intestine, peritoneum, ascending colon and descending colon. OUTCOMES: Gastrointestinal surgeon was invited during operation, and palliative gastrectomy was not performed because of extensive metastases. The patient died 30 days after caesarean section. LESSONS: This study present a case with advanced gastrointestinal cancer during pregnancy. We suggest that endoscopic exam is recommended if the patient is highly suspicious.
[Mh] Termos MeSH primário: Ascite/patologia
Carcinoma de Células em Anel de Sinete/patologia
Neoplasias Gastrointestinais/patologia
Hidrotórax/patologia
Complicações Neoplásicas na Gravidez/cirurgia
[Mh] Termos MeSH secundário: Adulto
Carcinoma de Células em Anel de Sinete/cirurgia
Progressão da Doença
Evolução Fatal
Feminino
Gastrectomia/métodos
Neoplasias Gastrointestinais/cirurgia
Seres Humanos
Hidrotórax/diagnóstico por imagem
Hidrotórax/cirurgia
Invasividade Neoplásica/patologia
Estadiamento de Neoplasias
Gravidez
Complicações Neoplásicas na Gravidez/patologia
Segundo Trimestre da Gravidez
Medição de Risco
Neoplasias Gástricas/patologia
Neoplasias Gástricas/cirurgia
Tomografia Computadorizada por Raios X/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009354


  6 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293530
[Au] Autor:Dey S; Parveen A; Tarrant KJ; Licknack T; Kong BC; Anthony NB; Rhoads DD
[Ad] Endereço:Program in Cell and Molecular Biology, University of Arkansas, Fayetteville, Arkansas, United States of America.
[Ti] Título:Whole genome resequencing identifies the CPQ gene as a determinant of ascites syndrome in broilers.
[So] Source:PLoS One;13(1):e0189544, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ascites syndrome is the most severe manifestation of pulmonary hypertension in fast-growing broilers. The disease can be attributed to increased body weights of birds, where the higher metabolic load is not matched by sufficient oxygen supply to the cells and tissues. Although there are environmental components, the disease exhibits moderate to high heritability. The current study uses high throughput whole genome resequencing (WGR) to identify genes and chromosomal regions associated with ascites. RESULTS: The WGR data identified the CPQ gene on chromosome 2. The association was confirmed by genotyping a large collection of DNAs from phenotyped birds from three distinct broiler lines using SNPs in intron 6 and exon 8 of the CPQ gene. By combining the genotype data for these two SNP loci, we identified three different alleles segregating in the three broiler lines. Particular genotypes could be associated with resistance to ascites. We further determined that particular genotypes most associated with resistance overexpress CPQ mRNA in three tissues which might explain the role of these alleles in contributing to resistance. CONCLUSIONS: Our findings indicate CPQ is an important determinant of pulmonary hypertension syndrome leading to ascites in broilers. We identified particular SNPs that can be used for marker-assisted selection of broilers for resistance to the disease. Our findings validate WGR as a highly efficient approach to map determinants contributing to complex phenotypic or disease-related traits. The CPQ gene has been associated with pulmonary hypertension in genome-wide association studies in humans. Therefore, ascites investigations in broilers are likely to provide insights into some forms of hypertension in humans.
[Mh] Termos MeSH primário: Ascite/genética
Genoma
Sequenciamento de Nucleotídeos em Larga Escala/métodos
[Mh] Termos MeSH secundário: Animais
Galinhas
Mapeamento Cromossômico
Estudo de Associação Genômica Ampla
Genótipo
Haplótipos
Hipertensão Pulmonar/genética
Reação em Cadeia da Polimerase
Polimorfismo de Nucleotídeo Único
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189544


  7 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27779544
[Au] Autor:Ba M; Long H; Zhang X; Tang Y; Wu Y; Wang S; Yan Z; Zhang B; Cui S
[Ad] Endereço:Intracelom Hyperthermic Perfusion Therapy Center, Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
[Ti] Título:Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer.
[So] Source:Int J Gynecol Cancer;26(9):1571-1579, 2016 11.
[Is] ISSN:1525-1438
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Malignant ascites, a complication often seen in patients with ovarian cancer (OC), is difficult to treat, but hyperthermic intraperitoneal chemotherapy (HIPEC) has a good efficacy. OBJECTIVE: The aim of this study was to assess the efficacy of cytoreductive surgery (CRS) combined with HIPEC for controlling malignant ascites from OC. MATERIALS AND METHODS: From December 2009 until December 2014, 53 patients with OC and malignant ascites were treated with CRS and HIPEC. Patients in good health condition were treated with CRS followed by HIPEC (CRS + HIPEC), and patients in poor health condition were treated initially with B-mode ultrasound-guided HIPEC followed by delayed CRS upon improvement of their health condition (HIPEC + delayed CRS). Resolution of ascites, complete CRS, overall survival, and disease-free survival were analyzed. RESULTS: All patients showed ascites regression. The total objective remission rate was 100%, even for patients in the poor condition group before CRS. Complete CRS was successful in 30 (88.23%) of 34 patients in the good condition group, and 17 (89.47%) of 19 patients in the poor condition group (P > 0.05). Median disease-free survival and median overall survival were 21 and 39 months in the good condition group, and 22 and 38 months in the poor condition group, respectively (P > 0.05). CONCLUSIONS: Hyperthermic intraperitoneal chemotherapy is effective at controlling ascites in patients with OC, even for patients in poor condition before CRS, or when complete CRS is not feasible. Furthermore, the regression of ascites appears not to be dependent on complete resection.
[Mh] Termos MeSH primário: Ascite/etiologia
Ascite/terapia
Procedimentos Cirúrgicos de Citorredução
Hipertermia Induzida
Neoplasias Ovarianas/complicações
[Mh] Termos MeSH secundário: Adulto
Idoso
China/epidemiologia
Feminino
Seres Humanos
Meia-Idade
Neoplasias Ovarianas/mortalidade
Neoplasias Ovarianas/terapia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  8 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262510
[Au] Autor:Liu YH; Wang LM; Wu JX; Rong WQ; Wu F; Li MH; Zhang Y; Lin ST; Zheng YL; Feng QF
[Ad] Endereço:Department of Hepatobiliary Surgery National Cancer Centre /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
[Ti] Título:[A prospective pilot study of combined intra-operative radiotherapy for centrally located hepatocellular carcinomas].
[So] Source:Zhonghua Zhong Liu Za Zhi;39(12):926-930, 2017 Dec 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To carry out a prospective cohort study of combined intra-operative radiotherapy for centrally located hepatocellular carcinomas (HCC) and to observe the safety and postoperative complications. A total of 79 patients with centrally located HCC who underwent hepatectomy were divided into two groups: experimental group (combined with targeted intra-operative radiotherapy, 32 cases) and control group (single surgical operation, 47 cases). Patients in the experimental group received intra-operative electron radiotherapy after tumor resection, while patients in the control group received to intra-operative electron radiotherapy.The haemorrhagia amount and operation time during the operation, intra-operative liver function and the recovery of liver and gastrointestinal tract of patients in these two groups were compared. No postoperative 30-day mortality was observed in all of the patients. The average total operation time of patients in the experimental group was (319±76) min, significantly longer than (233±76) min of the control group ( <0.001). The average aspartate transaminase (AST) level of patients in the experimental group at postoperative day 1 was 562.5 U/L, significantly higher than 347.0 U/L of control group ( =0.031). However, the average prothrombin activity levels of patients in the experimental group at postoperative day 3 and day 7 were (68.3±17.9)% and (73.4±10.2)%, respectively, significantly lower than (78.9±15.9)% and (80.0±10.6)% of control group (both <0.05). There were no significant differences of tumor volume, differentiation degree, satellite lesion, dorsal membrane invasion, microvascular invasion between these two groups (all >0.05). There were no significant differences of hospital stay, ventilation time, the incidence of hepatic insufficiency, ascites, pleural effusion, infection, biliary fistula between these two groups (all >0.05). There were no significant differences of alanine aminotransferase (ALT), albumin, total bilirubin between these two groups at postoperative day 1, 3, 5 and 7 (all of >0.05). The resection of centrally located HCC combined with intra-operative radiotherapy may increase the total operation time, delay the early postoperative recovery of liver function, but it is still safe and feasible. National Cancer Centre /Cancer Hospital, Chinese Academy of Medical Sciences, ChiCTR-TRC-12002802.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/radioterapia
Carcinoma Hepatocelular/cirurgia
Cuidados Intraoperatórios
Neoplasias Hepáticas/radioterapia
Neoplasias Hepáticas/cirurgia
[Mh] Termos MeSH secundário: Alanina Transaminase/sangue
Ascite/epidemiologia
Bilirrubina/sangue
Perda Sanguínea Cirúrgica
Carcinoma Hepatocelular/patologia
Hepatectomia
Seres Humanos
Incidência
Tempo de Internação
Neoplasias Hepáticas/patologia
Duração da Cirurgia
Projetos Piloto
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.6.1.2 (Alanine Transaminase); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2017.12.009


  9 / 12435 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267289
[Au] Autor:Chen Y; Bieber MM; Bhat NM; Teng NNH
[Ad] Endereço:Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University, Stanford, California, United States of America.
[Ti] Título:Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
[So] Source:PLoS One;12(12):e0187222, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Epithelial Ovarian Cancer (EOC) cells expression of a novel carbohydrate antigen was defined using a human VH4-34 encoded IgM monoclonal antibody (mAb216). MAb216 binds to a poly N-acetyllactosamine epitope expressed on B cells and kills normal and malignant B cells in vitro and in vivo. EOC patient ascites and EOC cell lines were used to study the anti tumor effect of mAb216. Various assays were used to characterize the epitope and demonstrate antibody-mediated binding and cytotoxicity in EOC. Drug and antibody combination effects were determined by calculating the combination index values using the Chou and Talalay method. MAb216 displays direct antibody mediated cytotoxicity on a population of human EOC tumor and ascites samples and EOC cell lines, which express high amounts of poly N-acetyllactosamine epitope, carried by CD147/CD98. Eighty four percent of patient samples, including platin resistant, had a tumor population that bound the monoclonal antibody. The binding pattern of mAb216 and mechanism of cytotoxicity was similar to that seen on normal and malignant B cells with unique general membrane disruption and "pore" formation. In vitro incubation with mAb216 and cisplatin enhanced killing of OVCAR3 cell line. In EOC cell lines percent cytotoxicity correlated with percent expression of epitope. Although in vitro data shows specific EOC cytotoxicity, for possible treatment of EOC MAb216 would need to be evaluated in a clinical trial with or without chemotherapy.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/imunologia
Antígenos de Neoplasias/imunologia
Imunoglobulina M/imunologia
Neoplasias Epiteliais e Glandulares/imunologia
Neoplasias Ovarianas/imunologia
[Mh] Termos MeSH secundário: Amino Açúcares/imunologia
Ascite/imunologia
Linhagem Celular Tumoral
Feminino
Seres Humanos
Microscopia Eletrônica de Varredura
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Amino Sugars); 0 (Antibodies, Monoclonal); 0 (Antigens, Neoplasm); 0 (Immunoglobulin M); 3Y5B2K5OOK (N-acetyllactosamine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0187222


  10 / 12435 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29188952
[Au] Autor:Arkkila P; Nordin A
[Ti] Título:Treatment of ascites and its complications.
[So] Source:Duodecim;132(18):1719-25, 2016.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:The underlying cause of ascites should always be treated if possible. Adhering to a low-salt diet is most important in the treatment of ascites. Diuretics are used in the treatment of clinically established and abundant ascites. The first-line drug in diuretic therapy is spironolactone, when necessary in combination with furosemide. The most important complications of ascites are hepatorenal syndrome and spontaneous bacterial peritonitis. The development of ascites lowers the quality of life, and is associated with significant mortality. Although new groundbreaking therapies are not available, prognosis of the patients is expected to be improved through optimization of current therapies.
[Mh] Termos MeSH primário: Ascite/complicações
Ascite/terapia
[Mh] Termos MeSH secundário: Ascite/mortalidade
Dieta Hipossódica
Diuréticos/uso terapêutico
Furosemida/uso terapêutico
Síndrome Hepatorrenal/etiologia
Seres Humanos
Peritonite/etiologia
Prognóstico
Qualidade de Vida
Espironolactona/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Diuretics); 27O7W4T232 (Spironolactone); 7LXU5N7ZO5 (Furosemide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE



página 1 de 1244 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde